昭衍新药2024中期报告

（於中華人民共和國註冊成立的股份有限公司）股份代號：6127 2024中期報告 2 6 7 9 10 11 26 44 46 48 50 51 H 1617 5100176 3485 5100176 H6127A603127 15323203-3207 108 35A509100033 https://www.joinnlabs.com 2024 20248 30 I. 2024202420246 302,585 II20,0002023202522,0002024 Non-GLP2023 2024 (1) 2024FDA GLPFDA3 GLP5FDA GLPGLP AMD GLP-1GCGHPVPBMC MSDADCPEGELISAqPCRELISPOTWB FLOWmRNAsiRNAPCRmRNA ADCPROTAC (2) CRO IIITIIIII ADCPROTAC(IHC)(MIF) (Alzheimers disease, AD)LC-MS/MSPCR (3) 2024(iPSCs)iPSCsiPSC(Nano-antibody)HINI (Homology Independent and Navigated Insertion) 2024 (4) 40P21215CNASGLPCHO/3T3NK 202429 92024 1.20% 2.(CNS)3.ADC4.CGTmRNAAD5.6.20241.4 II. 20246 30849.420236 301,012.116.1% 20246 30638.120236 30564.313.1% 20246 30211.324.9%20236 30447.844.2%20246 30 20246 3080.120236 3099.819.7% 20246 300.220236 3015.1 20246 30254.420236 30198.828.0% 20246 3012.220236 3011.92.5%20246 30 20246 30168.620236 30159.75.5%2024630 20246 3047.820236 3056.916.0%20246 30 20246 301.220236 301.725.7% 20246 305.120236 3027.4 20246 302.9%20236 3023.5% 20236 3089.520246 30172.220236 308.8%20246 3020.3% •20236 30447.852.8%20246 30211.3•235.4 20246 302,158.2202312 312,862.924.6% 202463018.1%2023123117.4% 20246 302,585 284.32023291.3 20246 3020246 30106.12023115.9 20246 30 20246 30 2024630 III. CRO IV. CROCRO (1)CRO 2024GLP 2024 22025Non-GLP 2024 (2) GLPGCP 1. 2. 3. 4. (3) (4) 1.BIOMEREBIOMERE 2.BDBIOMEREBDBIOMERE 3.GLP 20246 30 13.1313.14 13.15 13.20 13.21 20246 30XV352 (1)A167,160,633A20246 3022.29%A74,725,981A20246 309.96%A241,886,61420246 3032.26%A (2)L (3)2024630749,888,699630,893,493A1,768,814118,995,206HA 20246 30XVXV78352 20246 30XV233365% (1)L(2)2024630749,888,699630,893,493A1,768,814118,995,206HA(3)(1) 20246 30XV233365% 201820192020 (a) (b) 2020 (c) (d) 5% (e) A (f) 1%10% (g) 48 201820192020 (h) 60 (i) 122436 (i)50%1224(ii)30%2436(iii)20%3648 20192020(i)50%1224(ii)50%2436 (j) 48 (k) (i)1A11(ii)20A20A20A (i)1A1150%(ii)20A20A20A50% (l) (1) (2)(3)(4)(5) (m) (1)(2)(3)(4)A(5)AAA(6)(7)(8)(9)(10)(11) 20246 30A (1)20241 12020818,888(2)20246 302020818,888(3)201820192020818,8880.1%(4)20248 302020818,888A2020 20241 1 20221 19202211 182021A2021A2022A 20241 12021A2021A2022AA2021A2021A2022A 2022H 20226 242022H (a) 2022H(i)(ii)(iii) (b) 2022HH (c) (d) 2022HH (e) 2022H600H H 2022H (f) 2022H (i)(ii)(iii) (g) 2022H2022H20226 24102022H8 (h)H 2022HH 2022H 2022HH5,768,000H53,054,8420.77% 20243 28A100,000,00020243 281,735,600A28,277,143.40 H5,768,000H53,054,842 20246 301,768,814A 20246 30 20246 30 3.21 20246 3020246 30 20246 30 (i)20246 30 (ii) 20246 30 (iii) 2024420245 20246 30 (iv) 20246 30 20246 30II. H20212 2620213 1940,80020213 24H151.00H6,373.65,285.2 20238 30 20246 302,686.7 20246 30 20246 30 20246 30 20246 30 1. 20178 25A603127.SHH20212 266127.HK 2. 3420248 30 202420233 34 2023 202312 31 3. •1•1•16•77 4. (a) 4(b)15 20246 302,900202312 313,300 4. (b) • (i)(ii)(iii) • (i)(ii)(iii) • (i) 4. (b) (i) 4. (b) (iii) 5. 6. (a) 6. (b) 7.65%2024168,6005%100% 6. (c) 8. (a) 169,742,00020236 3090,627,000 (b) 169,742,00020236 3090,627,000 9. 120,148,00020236 3095,048,000 10. 10. (a) * 10. (b) 202312 3120246 30 20246 303580,00055 20246 3010%100,293,000202312 31146,462,000 (i)20244 18299,000,0002024629,900,000 12. 13. 20246 30335,968,00020236 30339,397,000 14. 15. (a) (b) 2145 18. 19. 20246 30 20. 21. (a) 21. (b) (c) 20246 3020236 303,156,000 22. (a) 22. (b) 23. (a) 20246 3020236 30 (b) 20246 2020232023 •20230.16 202320247 24. 25. (a) 13 (b) 25. (b) (i) 20246301,955,000 20246 30640,000 20246 301,533,000 25. (b) (i) 20246 30 26. 20246 30 27. (a) 27. 27. (b) (c) 2021Biorichland LLC 6,025,00042,938,00020246 30672,0004,772,000 2023 7,563,00020246 301,447,000 2023 2,429,00020246 30443,000 27. (d) (e) 20246 305,421,00020236 306,527,000